The cost of prescription drugs in the United States is a hot topic, especially when it comes to brand-name medications. While prices for these can be extremely high, generics—affordable alternatives—are making waves. In fact, generics account for 90% of all prescriptions in the U.S.
Americans enjoy lower prices for generic drugs compared to other developed nations, according to studies. However, the journey to get these savings can be long. This often depends on when the patents for brand-name drugs expire. A significant case currently being heard by the Supreme Court could change that landscape.
This case, called Hikma v. Amarin, involves Hikma, a generic drugmaker, and Amarin, the creator of Vascepa—a fish oil-based drug for heart disease. Their conflict revolves around “skinny labeling,” a strategy that allows generics to market drugs for unpatented uses sooner by skipping costly legal battles.
This method has brought over two dozen generic drugs to market in the last decade. A study showed that using skinny labeling helped Medicare save nearly $15 billion from 2015 to 2021. For instance, the generic version of Crestor, a cholesterol-lowering medication, appeared six years early due to this strategy. It saved patients and insurers around $8 billion in one year alone.
Now, Hikma successfully launched its generic version of Vascepa in 2020 with a skinny label, leveraging the unpatented uses of the drug. In response, Amarin sued, claiming Hikma was advertising its product inappropriately, potentially encouraging prescriptions for patented uses.
The ongoing debate raises questions about the future of drug pricing. Experts warn that if the Supreme Court rules in favor of Amarin, it may discourage generics from using skinny labels. This could lead to increased market delays for affordable alternatives, keeping medicine prices high for patients.
University of Alabama law professor Sean Tu argues that longer monopolies for brand-name drugs mean less access to affordable medications, resulting in poorer health outcomes for the public. On the flip side, University of Illinois law professor Jake Sherkow believes companies will continue to find ways to navigate any increased risks associated with skinny labels.
As the Supreme Court deliberates, its ruling could reshape the medical landscape. If the decision favors Hikma, patients may not see immediate relief in costs, but it might encourage more generics to flood the market. A ruling against Hikma could further entrench brand-name monopolies and potentially result in fewer new drug discoveries.
To gain broader insight into how such cases impact healthcare, check out this study on drug prices. The outcomes of these legal battles are crucial. They not only affect prices but also influence the availability of lifesaving medications in the future.
